Clinically non-functioning human pituitary adenomas
- PMID: 1623451
Clinically non-functioning human pituitary adenomas
Abstract
Clinically non-functioning pituitary adenomas are morphologically classified into two groups, those which have hormone immunoreactivity and ultrastructural features of known adenohypophysial cell types but are clinically silent, and those composed of cells that do not resemble nontumorous adenohypophysial cell types. Among the former are the silent somatotroph adenomas, silent corticotroph adenomas and silent gonadotroph adenomas; the latter include the silent type III adenomas, null cell adenomas and oncocytomas. We review their histological, immunohistochemical and ultrastructural features, the results of in situ hybridization to determine hormone synthesis by these tumors and data obtained from tissue culture characterizing their hormone release in vitro. Non-functioning adenomas represent a heterogeneous group. The discrepancies between morphology, immunoreactivity and lack of endocrine activity of silent adenomas are not clear. Oncocytomas are variants of null cell adenomas. We suggest that null cell adenomas and oncocytomas originate in uncommitted pluripotent precursor cells capable of undergoing multidirectional differentiation. The progenitor cells differentiate most frequently toward FSH/alpha-subunit producing cells; the mechanism of preferential differentiation is obscure.
Similar articles
-
A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.Neurosurgery. 2007 Sep;61(3):580-4; discussion 584-5. doi: 10.1227/01.NEU.0000290906.53685.79. Neurosurgery. 2007. PMID: 17881972
-
Pituitary hormone mRNA in null cell adenomas and oncocytomas by in situ hybridization comparison with immunohistochemical and clinical data.Pathol Res Pract. 2001;197(10):663-9. doi: 10.1078/0344-0338-00143. Pathol Res Pract. 2001. PMID: 11700887
-
Lentiviral vectors efficiently transduce human gonadotroph and somatotroph adenomas in vitro. Targeted expression of transgene by pituitary hormone promoters.J Endocrinol. 2004 Oct;183(1):217-33. doi: 10.1677/joe.1.05759. J Endocrinol. 2004. PMID: 15525589
-
Recent clinical and pathophysiological advances in non-functioning pituitary adenomas.Horm Res. 2009 Apr;71 Suppl 2:123-30. doi: 10.1159/000192449. Epub 2009 Apr 29. Horm Res. 2009. PMID: 19407508 Review.
-
Subclinical hyperfunctioning pituitary adenomas: the silent tumors.Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):447-60. doi: 10.1016/j.beem.2012.01.002. Epub 2012 May 22. Best Pract Res Clin Endocrinol Metab. 2012. PMID: 22863387 Free PMC article. Review.
Cited by
-
The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas.Front Endocrinol (Lausanne). 2019 May 22;10:330. doi: 10.3389/fendo.2019.00330. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31231308 Free PMC article. Review.
-
Computer-Assisted Microscope Analysis of Feulgen-Stained Nuclei in Gonadotroph Adenomas and Null-Cell Adenomas of the Pituitary Gland.Endocr Pathol. 1997 Summer;8(2):109-120. doi: 10.1007/BF02739939. Endocr Pathol. 1997. PMID: 12114631
-
Endothelial cell-specific molecule-1 as an invasiveness marker for pituitary null cell adenoma.BMC Endocr Disord. 2019 Aug 27;19(1):90. doi: 10.1186/s12902-019-0418-8. BMC Endocr Disord. 2019. PMID: 31455321 Free PMC article.
-
Proliferation markers in different types of clinically non-secreting pituitary adenomas.Pituitary. 1999 May;1(3-4):213-20. doi: 10.1023/a:1009933820856. Pituitary. 1999. PMID: 11081200
-
Identification of driver genes and key pathways of non-functional pituitary adenomas predicts the therapeutic effect of STO-609.PLoS One. 2020 Oct 29;15(10):e0240230. doi: 10.1371/journal.pone.0240230. eCollection 2020. PLoS One. 2020. PMID: 33119597 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical